Weight management/metabolic effects: GLP-1 RAs may also support weight management in adults with type 2 diabetes who are overweight or obese, providing an added metabolic advantage alongside their primary glycaemic and cardioprotective effects
Abstract Glucagon-like peptide 1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, represent highly effective treatment options for people with type 2 diabetes and obesity, enabling effective control of glucose and weight loss, while reducing cardiovascular and renal morbidity and mortality
But paying attention to food quality and portion sizes may still matter for results
Renzi A, Izzo D, Di Sarno G, Talento P, Torelli F, Izzo G, et al
The content provided here should not be construed as medical guidance